<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799914</url>
  </required_header>
  <id_info>
    <org_study_id>VS-01</org_study_id>
    <nct_id>NCT02799914</nct_id>
  </id_info>
  <brief_title>Evaluation of the Sinus-Venous Stent for the Treatment of Iliofemoral Venous Occlusive Disease</brief_title>
  <official_title>Evaluation of the Sinus-Venous Stent for the Treatment of Iliofemoral Venous Occlusive Disease: A Monocenter Post Market Clinical Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>be Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Archer Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>be Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post market clinical follow-up study about the Sinus-venous stent. Patients with venous&#xD;
      iliofemoral occlusive disease are treated with the Sinus-venous stent. This observational&#xD;
      study will provide 1 year data about safety and efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Difficult patient recruitment. No patients enrolled.&#xD;
  </why_stopped>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stent patency</measure>
    <time_frame>12 months</time_frame>
    <description>Patency broken down in primary patency, assisted primary patency and secondary patency</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>Index-procedure (intraoperative)</time_frame>
    <description>The index-procedure is the endovascular procedure in which the patient receives the device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revised venous clinical severity score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural complications</measure>
    <time_frame>Index-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reintervention</measure>
    <time_frame>12 months</time_frame>
    <description>Any peripheral venous intervention after the index-procedure to restore patency in the treated segment or outside the treated segment</description>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Venous Vascular Diseases and Syndromes</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sinus-Venous stent (Optimed GmbH)</intervention_name>
    <description>Stent implantation</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with venous iliofemoral occlusive disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age at study entry is at least 18 years.&#xD;
&#xD;
          2. Patient must sign the informed consent form prior to the index-procedure.&#xD;
&#xD;
          3. Patient suffers from acute or chronic venous occlusive disease indicated to be treated&#xD;
             with a venous stent.&#xD;
&#xD;
          4. Target lesion is located in the femoral vein, common femoral vein, external iliac&#xD;
             vein, or common iliac vein.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intolerance to anticoagulant medication.&#xD;
&#xD;
          2. Contra-indication for prolonged anticoagulant treatment.&#xD;
&#xD;
          3. Life expectancy less than 1 year.&#xD;
&#xD;
          4. Target vessel has been stented before.&#xD;
&#xD;
          5. Coagulopathy or known uncorrectable bleeding diathesis.&#xD;
&#xD;
          6. Recent (&lt;1 year) pulmonary embolism.&#xD;
&#xD;
          7. Pregnancy.&#xD;
&#xD;
          8. Known hypersensitivity to nitinol and/or nickel.&#xD;
&#xD;
          9. Known to be, or suspected of being unable to comply with the study protocol (e.g. no&#xD;
             permanent address, known to be non-compliant or presenting an unstable psychiatric&#xD;
             history).&#xD;
&#xD;
         10. Legal incapacity and/or other circumstances rendering the patient unable to understand&#xD;
             the nature, scope and possible impact of the study.&#xD;
&#xD;
         11. Patients in custody by juridical order.&#xD;
&#xD;
         12. Patients who do not agree to the transmission of their coded data within the liability&#xD;
             of documentation and notification.&#xD;
&#xD;
         13. Close affiliation with the investigational site: e.g. a close relative of the&#xD;
             investigator or a possibly dependent person (e.g. employee or student of the&#xD;
             investigational site).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert Lauwers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziekenhuis Oost-Limburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>December 7, 2015</study_first_submitted>
  <study_first_submitted_qc>June 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>February 7, 2019</last_update_submitted>
  <last_update_submitted_qc>February 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

